METABOLIC SYNDROME AND RISK OF CARDIOVASCULAR DISEASE WITH THYROID DISORDER

Authors

  • RAVI SHANKAR Department of Biochemistry, Pacific Institute of Medical Sciences, Udaipur, Rajasthan, India
  • NEHA SHARMA Department of Biochemistry, Shri Atal Bihari Vajpayee Government Medical College, Faridabad, Haryana, India
  • AJAY KUMAR Department of Biochemistry, Pacific Institute of Medical Sciences, Udaipur, Rajasthan, India
  • RAJU RAM Department of Biochemistry, M.K. Shah Medical College and Research Centre, Ahmadabad, Gujarat, India.
  • APARAJITA KUSHWAHA Department of Biochemistry, Pacific Medical College and Hospital, Udaipur, Rajasthan, India.

DOI:

https://doi.org/10.22159/ajpcr.2024v17i7.51844

Keywords:

insulin, ghrelin, Obestatin, Thyroid, metabolic syndrome

Abstract

Objectives: Metabolic syndrome (MetS) is the most widely used term for the aggregation of metabolic abnormalities, which leads to an increase in the risk of developing cardiovascular pathology. The prevalence of MetS is increasing all over the world with distinct evidence of high prevalence in India and other South Asian countries. Thyroid dysfunction, prominently subclinical hypothyroidism, has been observed more frequently in patients of MetS than in the general population.

Methods: This cross-sectional, observational study was conducted among MetS patients in the general population and near and dear of patients (350) at the Pacific Institute of Medical Sciences, Udaipur. For the determination of gastric peptidases (ghrelin and obestatin), insulin was done by enzyme-linked immunosorbent assay. Thyroid hormones are determined by chemiluminescence.

Results: The key findings in this analysis are the significant negative correlation between insulin and ghrelin. This inverse relationship was observed in individuals without cardiovascular disease (CVD), suggesting that even in the absence of overt CVD, insulin may play a role in regulating ghrelin levels. This finding is particularly noteworthy given ghrelin’s role in appetite regulation and energy balance.

Conclusion: The findings emphasize the need for a holistic approach to health assessment and management, considering individual factors such as age, sex, and the presence of underlying health conditions along with thyroid disorders.

Downloads

Download data is not yet available.

References

Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: Pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017;11(8):215-25. doi: 10.1177/1753944717711379, PMID: 28639538

Zimmet PZ, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782-7. doi: 10.1038/414782a, PMID: 11742409

Mohan V, Deepa M, Deepa R. The burden and determinants of undiagnosed diabetes in India: The cross-sectional, population-based, Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study. Lancet Diabetes Endocrinol. 2019;7:123-32.

Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S. Prevalence and trends of metabolic syndrome in the adult U.S. Population, 1999-2010. J Am Coll Cardiol. 2013;62(8):697-703. doi: 10.1016/j. jacc.2013.05.064, PMID: 23810877

Moore JX, Chaudhary N, Akinyemiju T. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, national health and nutrition examination survey, 1988-2012. Prev Chronic Dis. 2017;14:E24. doi: 10.5888/pcd14.160287, PMID: 28301314

Shantha GP, Kumar AA, Jeyachandran V, Rajamanickam D, Rajkumar K, Salim S, et al. Association between primary hypothyroidism and metabolic syndrome and the role of C reactive protein: A cross-sectional study from South India. Thyroid Res. 2009;2(1):2. doi: 10.1186/1756- 6614-2-2, PMID: 19272156

Udenze I, Nnaji I, Oshodi T. Thyroid function in adult Nigerians with metabolic syndrome. Pan Afr Med J. 2014;18:352. doi: 10.11604/ pamj.2014.18.352.4551, PMID: 25574328

Gyawali P, Takanche JS, Shrestha RK, Bhattarai P, Khanal K, Risal P, et al. Pattern of thyroid dysfunction in patients with metabolic syndrome and its relationship with components of metabolic syndrome. Diabetes Metab J. 2015;39(1):66-73. doi: 10.4093/dmj.2015.39.1.66, PMID: 25729715

Kota SK, Meher LK, Krishna S, Modi K. Hypothyroidism in metabolic syndrome. Indian J Endocrinol Metab. 2012;16(Suppl 2):S332-3. doi: 10.4103/2230-8210.104079, PMID: 23565417

Cell biolabs, Inc. Human Apo(a) ELISA Kit Catalog Number STA-359. San Diego: Cell Biolabs; 2012-2015.

Eagle Bioscience, Inc. Human Apo(B) ELISA Kit Catalog Number ARG81098. Nashua, NH: Arigo Biolaboratories; 2016.

Srikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K. Systematic review of metabolic syndrome biomarkers: A panel for early detection, management, and risk stratification in the West Virginian population. Int J Med Sci. 2016;13(1):25-38. doi: 10.7150/ijms.13800, PMID: 26816492

Lin SY, Li WC, Yang TA, Chen YC, Yu W, Huang HY, et al. Optimal threshold of homeostasis model assessment of insulin resistance to identify metabolic syndrome in a Chinese population aged 45 years or younger. Front Endocrinol (Lausanne). 2022;12:74674. doi: 10.3389/ fendo.2021.746747

McLaughlin T, Abbasi F, Lamendola C, Frayo RS, Cummings DE. Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls. J Clin Endocrinol Metab. 2004;89(4):1630-5. doi: 10.1210/jc.2003-031572, PMID: 15070922

Raji A, Seely EW, Arky RA, Simonson DC. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metab. 2001;86(11):5366-71. doi: 10.1210/ jcem.86.11.7992, PMID: 11701707

Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: Links, causes, and consequences. Arterioscler Thromb Vasc Biol. 2006;26(10):2200-7. doi: 10.1161/01.ATV.0000242905.41404.68, PMID: 16931789

Dos Santos Teixeira PF, Dos Santos PB, Pazos-Moura CC. The role of thyroid hormone in metabolism and metabolic syndrome. Ther Adv Endocrinol Metab. 2020;11:18-20. doi: 10.1177/2042018820917869, PMID: 32489580

Brenta G, Caballero AS, Nunes MT. Case finding for hypothyroidism should include type 2 diabetes and metabolic syndrome patients: A Latin American Thyroid Society (LATS) position statement. Endocr Pract. 2019;25(1):101-5. doi: 10.4158/EP-2018-0317, PMID: 30742573

Published

07-07-2024

How to Cite

RAVI SHANKAR, NEHA SHARMA, AJAY KUMAR, RAJU RAM, and APARAJITA KUSHWAHA. “METABOLIC SYNDROME AND RISK OF CARDIOVASCULAR DISEASE WITH THYROID DISORDER”. Asian Journal of Pharmaceutical and Clinical Research, vol. 17, no. 7, July 2024, pp. 68-73, doi:10.22159/ajpcr.2024v17i7.51844.

Issue

Section

Original Article(s)